"When our leaders talk about integration, what do they really mean? It's hypocrisy when they tell us to use outpatient [clinics], when they know mobile clinics exist because of their criminalisation ...

“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

A high-level panel discussion convened at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda drew together representatives from global funding foundations, ...

Artifical intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

One year ago, UNAIDS announced that the HIV response was at a critical crossroads. Apart from a handful of countries, the world was not on track to meet the ambitious 2030 goals: 95% of those ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

Two studies of children with HIV presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda showed that even if they are on antiretroviral therapy (ART) ...

Monthly oral PrEP pill advances to phase III trials Professor Kenneth Mayer at IAS 2025. ©Jacques Nkinzingabo/IAS. CC BY-SA 4.0. A once-monthly oral HIV prevention pill has shown promising results in ...

Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented yesterday at the 13th International AIDS Society Conference ...

Killer T-cells (CD8 cells or cytotoxic T-lymphocytes) engineered to mount a rare and specific reaction to HIV-infected cells that was first seen in an experimental vaccine more than a decade ago were ...